FIRST PATIENT SUCCESSFULLY DOSED
The first patient has enrolled in the Phase I clinical trial and was dosed on Sunday, April 14. No acute safety issues were reported.
TENBORON FEATURED ON FINNISH BIOINDUSTRIES’ WEBSITE
Tenboron’s background and BNCT technology are presented in this post: https://www.suomenbioteollisuus.fi/post/finnish-company-tenboron-develops-groundbreaking-cancer-treatment
Patient recruitment starts for Phase I clinical trial
Study preparations have been completed and necessary permits obtained. Data from the first patient(s) expected in Q1/2024.
Tenboron to present at the LSX Nordic Congress
Tenboron is a showcase company in this year’s LSX Nordic Congress which takes place in Copenhagen, Denmark on October 10-11.
TENBORON’S LEAD MOLECULE ENTERS CLINICAL STAGE
The Finnish Medicines Agency Fimea has approved Tenboron’s Phase I clinical trial application.The study will be conducted at the Helsinki University Hospital.Preparations for study initiation are underway.